Icon

Epinephrine - (1mg Base/ml; Solution, Intramuscular, Subcutaneous)

Epinephrine Belcher Pharma
1mg Base/ml; Solution, Intramuscular, Subcutaneous
Less Than $1000 mn
None None
More Than 5
None
None None
Epinephrine is a non-selective alpha and beta adrenergic agonist indicated: • To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. • For emergency treatment of allergic reactions (Type 1), including anaphylaxis. • For induction and maintenance of mydriasis during intraocular surgery.
Yes
******* *** ************* ********** ****** *** ***** **** ** **** ***** **** ****** '***(*** **, ****) *** **** ************ *********. ** ** ** ***** ***** ** ** ******** ** *********** ****.
Epinephrine Patent 1 Patent 2 Patent 3
******* (******) *** ** ** *** ** ********* *********
************* ********** ******* *** ******* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* (******) [***(*)*] ** *** ** ** *** ** ******** ******** ** *** **, ****
************* ********** ******* *** [***(*)*] ** ******* ******** ******** ** *** **, ****
  1. *** **, **** : ******* ***** * **** ******* ******* ** ******* ***** *** **** ***** **** ****** '***(*** **, ****).
  2. *** **, **** : ************* ********** ****** *** ******** ******* ****** ***** *** **** ** **** ***** **** ****** '***(*** **, ****).
  3. *** **, **** : ******* ***** * **** ******* ************* ********** ****** *** ** ******** ***** ** ********.
  4. *** **, **** : ****** ****** ***** * *********** ********* ******* ******* ****** ****** *** ***-************ ** ******* '*** (*** **, ****) *** '*** (*** **, ****) ** ****** *** *** ******* *******
  5. *** **, **** : ********** ********* **** ****** ******.
  6. *** *, **** : ******* ***** * **** ******* ******* ** ******* ***** *** **** ***** **** ******* '*** *** '***
  7. *** **, **** : ******* ******* **** ************* ********** ****** ** ******* *****.
  8. *** **, **** : ******* *** ** ** **** ****** '*** ** *** ***** ***** *******'* **** ***-**********.
  9. *** **, **** : * **** ** ** ***** *** ***** ** *** *** *******. (****)
  10. *** *, **** : ******* *** ** ** ** **** ******** *** **'* *********.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.